



UNIVERSITÀ  
DEGLI STUDI  
FIRENZE

## FLORE

# Repository istituzionale dell'Università degli Studi di Firenze

### **Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group)**

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

*Original Citation:*

Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group) / Bertolo, Riccardo; Autorino, Riccardo\*; Simone, Giuseppe; Derweesh, Ithaar; Garisto, Juan D.; Minervini, Andrea; Eun, Daniel; Perdonà, Sisto; Porter, James; Rha, Koon Ho; Mottrie, Alexander; White, Wesley M.; Schips, Luigi; Yang, Bo; Jacobsohn, Kenneth; Uzzo, Robert G.;

*Availability:*

The webpage <https://hdl.handle.net/2158/1153140> of the repository was last updated on 2019-04-15T15:48:31Z

*Published version:*

DOI: 10.1016/j.eururo.2018.05.004

*Terms of use:*

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

*Publisher copyright claim:*

Conformità alle politiche dell'editore / Compliance to publisher's policies

Questa versione della pubblicazione è conforme a quanto richiesto dalle politiche dell'editore in materia di copyright.

This version of the publication conforms to the publisher's copyright policies.

La data sopra indicata si riferisce all'ultimo aggiornamento della scheda del Repository FloRe - The above-mentioned date refers to the last update of the record in the Institutional Repository FloRe

(Article begins on next page)

1 **OUTCOMES OF ROBOT-ASSISTED PARTIAL NEPHRECTOMY FOR CLINICAL T2**  
2 **RENAL TUMORS: A MULTICENTER ANALYSIS (ROSULA\* COLLABORATIVE**  
3 **GROUP)**

4  
5 Riccardo Bertolo<sup>1,2</sup>, Riccardo Autorino<sup>3^</sup>, Giuseppe Simone<sup>4</sup>, Ithaar Derweesh<sup>5</sup>, Juan D. Garisto<sup>2</sup>,  
6 Andrea Minervini<sup>6</sup>, Daniel Eun<sup>7</sup>, Sisto Perdonà<sup>8</sup>, James Porter<sup>9</sup>, Koon Rha<sup>10</sup>, Alexander Mottrie<sup>11</sup>,  
7 Wesley M. White<sup>12</sup>, Luigi Schips<sup>13</sup>, Bo Yang<sup>14</sup>, Kenneth Jacobsohn<sup>15</sup>, Robert G. Uzzo<sup>16</sup>,  
8 Ben Challacombe<sup>17</sup>, Matteo Ferro<sup>18</sup>, Jay Sulek<sup>19</sup>, Umberto Capitanio<sup>20</sup>, Uzoma Anele<sup>3</sup>, Gabriele Tuderti<sup>3</sup>,  
9 Manuela Costantini<sup>3</sup>, Stephen Ryan<sup>5</sup>, Ahmet Bindayi<sup>5</sup>, Andrea Mari<sup>6</sup>, Marco Carini<sup>6</sup>, Aryeh Keehn<sup>7</sup>,  
10 Giuseppe Quarto<sup>8</sup>, Michael Liao<sup>9</sup>, Kidon Chang<sup>10</sup>, Alessandro Larcher<sup>11,20</sup>, Geert De Naeyer<sup>11</sup>,  
11 Ottavio De Cobelli<sup>18</sup>, Francesco Berardinelli<sup>13</sup>, Chao Zhang<sup>14</sup>, Peter Langenstroer<sup>15</sup>, Alexander Kutikov<sup>16</sup>,  
12 David Chen<sup>16</sup>, Nicolo De Luyk<sup>17</sup>, Chandru P. Sundaram<sup>19</sup>, Francesco Montorsi<sup>20</sup>, Robert J. Stein<sup>2</sup>,  
13 Georges Pascal Haber<sup>2</sup>, Lance J. Hampton<sup>3</sup>, Prokar Dasgupta<sup>17</sup>, Michele Gallucci<sup>4</sup>, Jihad Kaouk<sup>2</sup>,  
14 Francesco Porpiglia<sup>1</sup>

15  
16 <sup>1</sup>Dept of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy; <sup>2</sup>Dept of Urology,  
17 Cleveland Clinic, Cleveland, OH, USA; <sup>3</sup>Division of Urology, VCU Health, Richmond, VA, USA; <sup>4</sup>Dept of  
18 Urology, "Regina Elena" National Cancer Institute, Rome, Italy; <sup>5</sup>Department of Urology, UCSD Health  
19 System, La Jolla, CA, USA; <sup>6</sup>Department of Urology, University of Florence, Careggi Hospital, Firenze,  
20 Italy; <sup>7</sup>Dept. of Urology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA;  
21 <sup>8</sup>Division of Urology, Pascale Foundation, Institute for Cancer Research and Care, Napoli, Italy;  
22 <sup>9</sup>Swedish Urology Group, Seattle, WA, USA; <sup>10</sup>Urological Science Institute, Yonsei University College of  
23 Medicine, Seoul, Korea; <sup>11</sup>Department of Urology, OLV Hospital, Aalst, Belgium; <sup>12</sup>Dept of Urology,  
24 University of Tennessee Medical Center, Knoxville, TN, USA; <sup>13</sup>Department of Urology, Annunziata  
25 Hospital, Dept. of Urology, Chieti, Italy; <sup>14</sup>Dept. of Urology, Changhai Hospital, Shanghai, China;  
26 <sup>15</sup>Dept. of Urology, Medical College Wisconsin, Milwaukee, WA, USA; <sup>16</sup>Department of Urology, Fox  
27 Chase Cancer Center, Philadelphia, PA, USA; <sup>17</sup>Dept. of Urology, Guy's Hospital, King's College,  
28 London, UK; <sup>18</sup>Dept of Urology, IEO, Milan, Italy; <sup>19</sup>Dept of Urology, Indiana University, Indianapolis,  
29 IN, USA; <sup>20</sup>Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San  
30 Raffaele, Milan, Italy

31  
32  
33  
34

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

**^Correspondence:** Riccardo Autorino, MD, PhD, FEBU - Clinical Associate Professor of Urology, Virginia Commonwealth University - West Hospital, 7<sup>th</sup> floor, 1200 East Broad st, Richmond, VA, 23298, USA - Phone: +1 8046752169 - email: [ricautor@gmail.com](mailto:ricautor@gmail.com)

\*RObotic SURgery for LARge renal mass (ROSULA) project

**Abstract Word Count:** 326; **Manuscript Word Count:** 2773

**Keywords:** *partial nephrectomy, robot-assisted; renal neoplasm; renal mass, clinical T2; outcomes*

**ABSTRACT**

**Background:** While partial nephrectomy (PN) represents the standard surgical management for cT1 renal masses, its role for cT2 tumors is controversial. Robotic assisted PN is being increasingly implemented worldwide.

**Objective:** To analyze perioperative, functional, oncological outcomes of robot-assisted PN (RAPN) for cT2 tumors.

**Design, setting, and participants:** Retrospective analysis of a large multicenter multi-national dataset of patients with non-metastatic cT2 masses treated with robotic surgery (ROSULA: RObotic SURgery for LARge renal mass).

**Intervention:** Robotic assisted PN (RAPN).

**Outcome measurements and statistical analysis:** Patients’ demographics, lesion characteristics, perioperative variables, renal functional data, pathology and oncological data were analyzed. Univariable and multivariable regression analyses assessed the relationships with the risk of intra-/post-operative complications, recurrence and survival.

1 **Results and limitations:** 298 patients were analyzed. Median tumor size was 7.6 cm (7-8.5).  
2 Median RENAL score was 9 (8-10). Median ischemia time was 25 min (20-32). Median  
3 estimated blood loss was 150 ml (100-300). Sixteen patients had intraoperative  
4 complications (5.4%), whereas 66 (22.1%) had postoperative complications (5.0% were  
5 Clavien grade  $\geq 3$ ). Multivariable analysis revealed that lower RENAL score (OR 0.46,  
6  $p=0.021$ ) and confirmed pathological pT2 stage (OR 0.51,  $p=0.001$ ) were protective against  
7 postoperative complications. 243 lesions (81.6%) were malignant. Twenty patients (8.2%)  
8 had positive surgical margins. Ten deaths and 25 recurrences/metastases occurred at a  
9 median follow-up of 12 months (5-35). At univariable analysis, higher pT stage was  
10 predictive of likelihood of recurrences/metastases ( $p=0.05$ ). ANOVA test showed significant  
11 deterioration of renal function at discharge, while remaining stable over time at 1-yr follow-  
12 up. Main limitation of this study is the retrospective design.

13 **Conclusions:** RAPN in setting of select cT2 renal masses can be safely performed with  
14 acceptable outcomes. Further studies are warranted to corroborate our findings and to better  
15 define the role of robotic nephron-sparing for this challenging indication.

16  
17 **Patient summary:** This report shows that robotic surgery can be used for safe removal of a  
18 large renal tumor in a minimally invasive fashion, maximizing preservation of renal function,  
19 and without compromising cancer control.

20  
21  
22  
23  
24

1 **1. Introduction**

2 Current guidelines recommend partial nephrectomy (PN) as the standard surgical  
3 treatment for clinical T1a renal tumors, whenever technically feasible [1, 2], given better  
4 renal functional preservation compared to radical nephrectomy (RN) [3]. However, for larger  
5 localized renal tumors, RN is still regarded as the reference standard, despite emerging data  
6 suggesting a potential role for a nephron-sparing approach in selected cases [4]. For T1b  
7 renal masses, PN was shown to provide to be not inferior to RN in terms of cancer control [5-  
8 7]. Recent reports, mainly limited to open surgery series, suggest that even in patients with  
9 larger masses (> 7 cm, clinical T2), PN does not compromise cancer-specific mortality [8-  
10 10].

11 With the diffusion of robotic daVinci surgery, experience with robot-assisted PN  
12 (RAPN) has exponentially grown over the last decade, and this has led to broaden the  
13 utilization of the procedure to more complex tumors. However, RAPN for clinical T2 renal  
14 masses represents a challenging intervention, and very few case series have been reported to  
15 date [11-16].

16 The aim of the present study was to analyze the perioperative, functional and  
17 oncological outcomes of RAPN for cT2 tumors in a large multi-institutional dataset (RObotic  
18 SURgery for LArge renal mass – ROSULA project).

19  
20 **2. Materials and Methods**

21 **2.1. Study design**

22 The ROSULA is a multi-center multi-national project including 22 robotic centers  
23 worldwide. A dataset of patients consecutively underwent robotic surgery either by radical or  
24 nephron sparing approach for  $\geq$  cT2 renal masses was created. Institutional Review Board

1 approval or exempt was obtained at each Center. The purpose-built ROSULA database was  
2 queried for patients with non-metastatic cT2 renal masses who had undergone RAPN at 19 of  
3 participating institutions during the study period (July 2007 – Sep 2017) (**Suppl. Figure 1**).

4 The following parameters were collected:

- 5 a. patients' baseline characteristics (age, gender, race, body mass index [BMI],  
6 ASA score, presence of diabetes mellitus, hypertension or preoperative  
7 chronic kidney disease [CKD] stage  $\geq$  III, solitary kidney status, preoperative  
8 hemoglobin, serum creatinine and estimated Glomerular Filtration Rate, as  
9 calculated by the MDRD formula [17];
- 10 b. tumor characteristics (side, clinical size, clinical stage according to TNM [18],  
11 cystic features, RENAL nephrometry score (tumor complexity was graded as  
12 low, moderate and high, RENAL score 4–6, 6–9 and 10–12, respectively  
13 [19]);
- 14 c. perioperative variables (transperitoneal vs retroperitoneal approach, operative  
15 time, warm ischemia time, percentage of clamp-less and cold ischemia  
16 technique procedures, estimated blood loss [EBL], intra-operative  
17 complications [including transfusions], conversions, and postoperative  
18 complications [graded according to the Clavien-Dindo system [20] –  
19 complications  $\geq$  grade III were considered as major], length of hospital stay  
20 and hemoglobin at discharge;
- 21 d. pathology data (pathologic tumor size, pathologic stage according to TNM,  
22 tumor histology according to the 2004 World Health Organization criteria

1 [21], tumor grade according to Fuhrman [22], margin status, presence of  
2 sarcomatoid differentiation, presence of tumor thrombus).

- 3 e. Functional data, including serum creatinine and eGFR at discharge and at 1, 6  
4 and 12 postoperative months. Postoperative “early” (at discharge) acute renal  
5 injury (AKI) was defined according to the RIFLE (Risk of renal dysfunction,  
6 Injury to the kidney, Failure of kidney function, Loss of kidney function and  
7 End-stage kidney disease) criteria [23].
- 8 f. Oncological data, including tumor recurrence, tumor metastasis, cancer-  
9 specific mortality.

## 11 *2.2. Study objectives*

12 Primary study endpoint was the assessment of surgical (perioperative) outcomes. In  
13 this regard, as a surrogate of surgical quality, a “trifecta” outcome was used, which included  
14 negative surgical margins, no perioperative complications, and WIT  $\leq$  25 minutes [24].

15 Secondary endpoints were the short term (1 year) functional and oncological outcomes.

## 17 *2.3. Statistical analysis*

18 Means + standard deviations (SD) were used to report variables with a normal  
19 distribution; medians and interquartile ranges (IQR) in case of variables with a non-normal  
20 distribution instead. Frequencies and proportions were used to report categorical variables.

21 The means of continuous and categorical variables were compared by using the student T-  
22 and the Chi-square tests, respectively. ANOVA test was used to compare more than two  
23 groups.

1           Univariable and multivariable forward stepwise logistic regression analyses assessed  
2 the relationships of variables of interest with the risk of: (a) intraoperative complications, (b)  
3 overall postoperative complications, and (c) postoperative renal dysfunction as defined  
4 according to the RIFLE criteria.

5           Univariable analyses were used to test the effect of variables of interest on the  
6 probability of recurrences or metastases. Due to the small number of cancer-related deaths,  
7 the analysis was avoided for this outcome. Significance level was set at p-value < 0.05.  
8 Statistical analysis was performed using Statistic 8.0 Software (Tulsa, Oklahoma, US).

9

### 10 **3. Results**

11           Two-hundred ninety-eight patients who underwent RAPN for cT2 renal mass were  
12 included in the analysis. In **supplementary Table 1**, number of cases per Institution is  
13 provided. A trend towards a higher number of cases was observed during the study period  
14 (**Figure 1**). Patients' baseline characteristics are reported in **Table 1**. Median clinical tumor  
15 size was 7.6 (IQR: 7-8.5) cm. Median RENAL score was 9 (IQR: 8-10).

16

#### 17 **3.1. Surgical outcomes**

18           Only 8.4% of the procedures were performed by retroperitoneal approach. Mean  
19 operative time was  $163 \pm 75$  minutes. Twenty-two (7.4%) procedures were performed by  
20 clamp-less approach. Median ischemia time was 25 (IQR: 20-32) minutes, with 5% of  
21 procedures performed by cold ischemia technique. Median estimated blood loss (EBL) was  
22 150 ml (100-300). Sixteen patients had intraoperative complications (5.4%). Fifteen patients  
23 received intraoperative blood transfusions (5%), and one conversion to RN occurred (0.3%),  
24 which was due to sticky fat possibly compromising the oncological efficacy in soft large

1 mass with high risk of rupture. The detailed list of perioperative data and complications is  
2 reported in **Table 2**. Sixty-two patients (20.8%) had postoperative complications. Among  
3 these, fifteen had a major (Clavien grade  $\geq 3$ ) complication (5%).

4 Median length of hospitalization was 4 days (3-5). At discharge, hemoglobin was  
5 significantly reduced with respect to baseline ( $13.8 \pm 1.7$  vs  $10.4 \pm 3.0$ ;  $p < 0.001$ ).

6 At univariable analysis, EBL and BMI were predictors of intraoperative  
7 complications ( $p < 0.001$  and  $= 0.001$ , respectively). Clinical tumor size ( $< 0.001$ ) and pT  
8 stage 3 vs 2 ( $p = 0.003$ ) were predictors of postoperative complications. Multivariable  
9 logistic regression demonstrated that simple RENAL score (4-6) and non-pathological  
10 upstaging (pT2) were independently associated with a decreased risk of development of  
11 complications (OR 0.46,  $p = 0.021$  and OR 0.51,  $p = 0.001$ , respectively).

### 12 **3.2. Renal functional outcomes**

13 ANOVA test showed significant deterioration of renal function at discharge (median  
14 decrease 17.5%,  $p$ -values  $< 0.001$ ), while at 1-yr follow-up both SCr and eGFR were  
15 comparable to their discharge value ( $p = 0.798$  and  $0.159$ , respectively) (**Supplementary**  
16 **Figure 2**). Out of 180 patients who had complete eGFR data preoperatively and at discharge,  
17 sixty-two patients (34.4%) experienced postoperative AKI (**Table 2**). On multivariate  
18 analysis, preoperative eGFR  $< 60$  ml/min/1.73<sup>m2</sup>, increasing clinical tumor size (every 1 cm),  
19 and preoperative diabetes mellitus were independent predictors of postoperative AKI (OR =  
20 2.61, 1.98 and 5.13,  $p < 0.001$ ,  $= 0.009$  and  $0.018$ , respectively - **Table 3**).

### 21 **3.3. Oncological outcomes**

22 Pathology data are detailed in **Table 4**. Median size at final pathology was 7.4 cm  
23 (IQR 6.4-8.2). Most of the lesions were malignant ( $n = 243$ ; 81.6%). Among malignant

1 lesions, 58 % were Fuhrman grade 1-2 (or without grading), and 42% Fuhrman grade 3-4. In  
2 9 cases a sarcomatoid differentiation was found. Twenty patients (8.2%) had positive  
3 surgical margins. Forty-two patients (17.2%) were down-staged to pT1a-b, whereas 93  
4 (38.3%) were upstaged to pT3-4 at final pathology. Among the 63 patients who underwent  
5 lymph-nodes dissection, only one patient had nodal involvement (pN1).

6 Twenty-five recurrences or progression to metastasis (actuarial progression rate:  
7 10.3%) were observed and 2 deaths (0.7%) related to metastatic renal cancer occurred after a  
8 median follow-up of 12 months.

9 At univariable Cox regression, pT3a pathological upstaging was the only significant  
10 predictor of recurrence/metastasis ( $p = 0.05$ , **Figure 2A**); tumor thrombus, higher Fuhrman  
11 grade (3-4) and sarcomatoid differentiation showed a trend towards significance (**Figure 2B**  
12 and **Figure 3A, B**, respectively).

13

#### 14 **3.4. Trifecta**

15 A “trifecta” outcome was achieved in 120 (49.4%) patients among the 243 patients  
16 who had malignant lesions.

17

#### 18 **4. Discussion**

19 To the best of our knowledge, this represents the largest series of RAPN for cT2 renal  
20 masses to date. The present analysis relies on a robust sample from various Institutions  
21 worldwide with an established robotic program, and it allows to draw some interesting  
22 conclusions about this “extreme” indication for a robotic nephron-sparing approach. Overall,  
23 we found RAPN for cT2 renal masses to be safely feasible, with acceptable perioperative and  
24 functional outcomes.

1           In a recent systematic review, Mir et al found only 4 studies comparing PN to the  
2 “gold standard” RN in the subset of patients with cT2 tumors. In their analysis, PN was  
3 found to have significantly higher blood losses and likelihood of complication rates.  
4 Nonetheless, these PN in these comparative analyses were performed with open and  
5 laparoscopic, as opposed to robotic approach. [4].

6           Studies on robotic nephron-sparing surgery for larger masses remain quite sparse and  
7 limited [11-14]. Malkoc et al. recently reported a single center study comparing a series of 54  
8 robotic to 56 open partial nephrectomies for >7 cm renal tumors [15]. RAPN was found to be  
9 superior to the open approach, but median ischemia time was above 30 minutes in both the  
10 approaches. The incidence of overall complications was 18.5 % and 28.6 %, in favor of  
11 robotic, with a major complications rate of 3.7 % and 12.5 %, respectively. Complications  
12 rate of RAPN for highly complex renal masses were reported to be almost the same in a  
13 recent prospective series by Porpiglia et al., with 23.8% and 4.8 of overall and major  
14 complications, respectively [25].

15           Of note, the results from our multicenter study confirmed that even in case of cT2  
16 renal tumors, the robotic approach allows for acceptable ischemia time (median 25 min) [26],  
17 and complication rates (21% overall, 5% major complications). If data on complications are  
18 slightly higher than what previously reported for RAPN [11-16], they appear to be  
19 consistently lower to series reporting complications for T2 open PN [6, 15]. Our findings that  
20 increasing tumor complexity and tumor size are predictive of postoperative complications are  
21 consistent with recent reports from large national and institutional databases. [27, 28]. Our  
22 reported Trifecta rate of 49.4% is lower than reports from series with small renal masses.  
23 Nonetheless, given that predictors for Trifecta include increasing tumor complexity or size,

1 our findings are not surprising. Interestingly, our findings are similar to those of Abdel  
2 Raheem and co-workers published who reported a Trifecta rate of 37.5% when examining  
3 Trifecta rates in patients undergoing PN for complex renal masses [29].

4         Regarding the functional data, one-third of the patients experienced postoperative  
5 AKI, as assessed by RIFLE criteria [23]. Similar rates were reported in a large sample of PN  
6 procedures by Rajan et al [30]. AKI was found to correlate by baseline patient's factors like  
7 eGFR and diabetes, as also reported by others [31]. More interestingly, tumor size was also a  
8 predictor of postoperative AKI, which can be explained by larger excision of renal  
9 parenchyma. In this respect, Zhang et al reported that parenchymal mass reduction and  
10 ischemia both contribute to acute changes after PN, and while postoperative AKI is  
11 associated with suboptimal recovery, even patients with grade 2/3 AKI up to 90% of  
12 recovery can be expected [32]. In our analysis, while eGFR was found overall to be  
13 significantly reduced at 1 month postoperatively more than 15%, it remained stable over  
14 time, which is in line with previous findings [33].

15         Notably, a significant proportion of patients experienced up-staging to pT3a after PN.  
16 Up-staged pT3a patients had worsened recurrence/metastasis free survival across all clinical  
17 tumor stages after PN. In a recent single institution analysis, Mouracade and colleagues  
18 evaluated on more than 1000 patients with cT1 staged renal masses the perioperative  
19 morbidity, oncological outcome and predictors of pT3a upstaging after partial nephrectomy  
20 [34]. They found that male gender and R.E.N.A.L. score were preoperative predictors of  
21 upstaging. In our multicenter cohort, we had 70% of male patients and a median RENAL  
22 score of 9. In our study, while we noted several factors trending towards significance as

1 predictors for recurrence or metastases, none reached statistical significance. This is most  
2 likely a limitation due to the short follow up of our cohort.

3         While the adoption of a nephron sparing approach for higher risk masses might be  
4 concerning from an oncological standpoint, population-based studies suggest that even in  
5 patients with adverse pathologic features, PN does not seem to compromise cancer-specific  
6 mortality, and therefore the decision to perform a PN should mostly rely on the technical  
7 feasibility [35]. In our series, the high pT3 staged tumors (33%) might be one explanation for  
8 the 8% rate of positive surgical margins. Indeed, 10 patients (50%) who had positive surgical  
9 margins were upstaged to pT3. Moreover, if one considers the open surgery literature  
10 specifically regarding the larger masses, this rate compares favorably. Indeed, in a recent  
11 review the range of positive surgical margins for these cases was found to be 0 to 31% [36].  
12 In support of our data, in the Mouracade study pT3a tumors had 18.6% of positive surgical  
13 margins rate [34]. Using the US National Cancer Database, Fero et al. reported an overall  
14 increased rate of positive margins at 7.3%, driven by increasing use of minimally invasive  
15 approaches, and not by higher clinical stage [37].

16         Moreover, in a multicenter retrospective survey, Bensalah and co-authors analyzed  
17 111 patients with PSM, concluding that PSM status more likely occurs when surgery is  
18 imperative, as could be the case of more complex renal lesions. In that study, PSM status did  
19 not influence cancer-specific survival but it was associated with increased risk of recurrence  
20 [38]. More recently, Khalifeh and colleagues found an 18-fold higher risk for recurrence in  
21 case of PSM, after adjusting for multiple tumors, tumor size, tumor growth pattern and  
22 pathological stage [39].

1           Concerning the oncological outcomes, our analysis showed an actuarial rate of 8.6%  
2 of recurrences or metastases, with 2 cancer-related deaths (0.7% actuarial cancer-specific  
3 mortality) occurred after a median follow-up of 12 months. Such findings could be read as  
4 satisfactory too. Indeed, even if there is still limited retrospective evidence about the  
5 oncological efficacy of PN for renal tumors larger than 7 cm, the available literature data  
6 reported in a recent review with follow-up range of 13.1 to 70 months showed 5-year  
7 progression-free survival and 5-year overall survival ranging from 71 to 92.5% and from 66  
8 to 94.5%, respectively [36].

9           Our study is not devoid of limitations. First and foremost, the retrospective design  
10 accounts for some inherent biases, including patient selection and differences in surgical  
11 technique. It was beyond the scope of the present analysis to compare RAPN to the reference  
12 standard RN, and therefore a control arm was not considered. Also, the available follow-up  
13 of this cohort was limited (median 12 months), and it did not allow evaluating long term  
14 outcomes. One might argue that would be interesting to know how many cT2 renal masses  
15 were seen at these institutions during the time-period of the study to gauge the level of  
16 selection bias and to determine if most patients with cT2 masses offered robotic PN and how  
17 patients were ultimately selected for a robotic vs open partial approach. Unfortunately, we do  
18 not have this detailed information. The choice of one approach (robotic) versus the other  
19 (open) was at discretion of each surgeon. Having said that, the aim of the study was not to  
20 determine “practice patterns” of management of these large renal masses at participating  
21 institutions, but rather to report their experience with the robotic PN for this “extreme”  
22 indication. Concerning the evaluation of renal function, we concur that while the use of  
23 eGFR is a practical viable option, ideally a nuclear renal scan should be adopted [17].

1 However, this was not available for this study. Last, no centralized radiologic or pathologic  
2 review was performed for the here reported cases.

3 Notwithstanding these limitations, this series represents the largest describing the  
4 outcomes of mostly elective RAPN for large (clinical stage T2) renal masses in a “real-life”  
5 scenario. On the other hand, these study findings may not be generalizable to the entire  
6 urologic community, and they are reserved for experienced robotic surgeons/centers of  
7 excellence. Even though cT1a and certainly cT1b tumors may be challenging for most, and  
8 PN remains overall underused for these “standard” indications. Future definition of  
9 maximum tumor threshold and more accurate preoperative staging are mandatory to optimize  
10 the outcomes. Moreover, image-guidance technology could aid in expanding the role of  
11 RAPN for these challenging indications [40].

12

### 13 **Conclusions**

14 RAPN in case of large renal masses can be safely performed with acceptable  
15 outcomes. Further studies are warranted to corroborate our findings and to better define the  
16 role of RAPN for this challenging indication. For the time being, the decision to proceed with  
17 robotic nephron sparing surgery should be weighted based on the technical feasibility and  
18 patient’s individualized competing risk of morbidity and cancer related events.

19

20

21

22

23

24

## 1   **References**

- 2       1. Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma:  
3       2014 update. *Eur Urol* 2015; 67:913–24.
- 4       2. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the  
5       clinical T1 renal mass. *J Urol* 2009; 182:1271–9.
- 6       3. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC  
7       intergroup phase 3 study comparing the oncologic outcome of elective nephron-  
8       sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *Eur Urol*  
9       2011; 59:543–52.
- 10      4. Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie M, Autorino R. Partial  
11      Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A  
12      Systematic Review and Meta-analysis of Comparative Studies. *EurUrol* 2017; 71:  
13      606-617.
- 14      5. Weight CJ, Miller DC, Campbell SC, et al. The management of a clinical T1b renal  
15      tumor in the presence of a normal contralateral kidney. *J Urol* 2013; 189:1198–202.
- 16      6. Porpiglia F, Mari A, Bertolo R, et al. Partial Nephrectomy in Clinical T1b Renal  
17      Tumors: Multicenter Comparative Study of Open, Laparoscopic and Robot-assisted  
18      Approach (the RECORD Project). *Urology*. 2016; 89:45-51.
- 19      7. Badalato GM, Kates M, Wisnivesky JP, Choudhury AR, McKiernan JM. Survival  
20      after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell  
21      carcinoma (RCC) in the USA: a propensity scoring approach. *BJU Int* 2012;  
22      109:1457–62.

- 1 8. Kopp RP, Mehrazin R, Palazzi KL, et al. Survival outcomes after radical and partial  
2 nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry  
3 score. *BJU Int* 2014; 114:708–18.
- 4 9. Long CJ, Canter DJ, Kutikov A, et al. Partial nephrectomy for renal masses  $\geq 7$  cm:  
5 technical, oncological and functional outcomes. *BJU Int* 2012; 109:1450–6.
- 6 10. Becker F, Roos FC, Janssen M, et al. Short-term functional and oncologic outcomes  
7 of nephron-sparing surgery for renal tumours  $\geq 7$  cm. *Eur Urol* 2011; 59:931–7.
- 8 11. Ficarra V, Bhayani S, Porter J, et al. Robot-assisted partial nephrectomy for renal  
9 tumors larger than 4 cm: results of a multicenter, international series. *World J Urol.*  
10 2012; 30(5):665-70. doi: 10.1007/s00345-012-0943-9.
- 11 12. Brandao LF, Zargar H, Autorino R, et al. Robot-assisted partial nephrectomy for  $\geq 7$   
12 cm renal masses: a comparative outcome analysis. *Urology* 2014; 84:602–8.
- 13 13. Gupta GN, Boris R, Chung P, Linehan WM, Pinto PA, Bratslavsky G. Robot-assisted  
14 laparoscopic partial nephrectomy for tumors greater than 4 cm and high nephrometry  
15 score: feasibility, renal functional, and oncological outcomes with minimum 1 year  
16 follow-up.
- 17 14. Serni S, Vittori G, Frizzi J, et al. Simple enucleation for the treatment of highly  
18 complex renal tumors: Perioperative, functional and oncological results. *Eur J Surg*  
19 *Oncol.* 2015; 41(7):934-40.
- 20 15. Malkoc E, Ramirez D, Kara O, Maurice MJ, Nelson RJ, Caputo PA, Kaouk JH.  
21 Robotic and open partial nephrectomy for localized renal tumors larger than 7 cm: a  
22 single-center experience. *World J Urol.* 2017; 35(5):781-787.

- 1 16. Masson-Lecomte A, Yates DR, Bensalah K, et al. Robot-assisted laparoscopic  
2 nephron sparing surgery for tumors over 4 cm: operative results and preliminary  
3 oncologic outcomes from a multicentre French study. *Eur J Surg Oncol* 2013;  
4 39:799–803.
- 5 17. Bertolo RG, Zargar H, Autorino R, et al. Estimated glomerular filtration rate, renal  
6 scan and volumetric assessment of the kidney before and after partial nephrectomy: a  
7 review of the current literature. *Minerva Urol Nefrol.* 2017 Dec;69(6):539-547.
- 8 18. Novara G, Ficarra V, Antonelli A, et al. Corrigendum to "Validation of the  
9 2009 TNM Version in a Large Multi-Institutional Cohort of Patients Treated  
10 for Renal Cell Carcinoma: Are Further Improvements Needed?" [*Eur Urol* 2010;  
11 58:588-95]. *Eur Urol.* 2011 Jan;59(1):182. doi: 10.1016/j.eururo.2010.10.017. Epub  
12 2010 Oct 15. No abstract available.
- 13 19. Kutikov A, Smaldone MC, Egleston BL et al. Anatomic features of enhancing renal  
14 masses predict malignant and high-grade pathology: a preoperative nomogram using  
15 the RENAL nephrometry score. *Eur Urol* 2011; 60: 241–8
- 16 20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new  
17 proposal with evaluation in a cohort of 6336 patients and results of a survey. *Surgery*  
18 2004; 240:205-13.
- 19 21. Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the  
20 Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic  
21 Cancers. *Eur Urol.* 2018 Jan 8. pii: S0302-2838(17)31064-3. doi:  
22 10.1016/j.eururo.2017.12.018. [Epub ahead of print] Review. PubMed PMID:

- 1 22. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters  
2 in renal cell carcinoma. *Am J Surg Pathol* 1982; 6:655–63.
- 3 23. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P and the ADQI workgroup.  
4 Acute renal failure – definition, outcome measures, animal models, fluid therapy and  
5 information technology needs: the Second International Consensus Conference of the  
6 Acute Dialysis Quality Initiative (ADQI) Group. *Critical Care* 2004 Aug; 8(4):R204-  
7 212.
- 8 24. Zargar H, Porpiglia F, Porter J, et al. Achievement of trifecta in minimally invasive  
9 partial nephrectomy correlates with functional preservation of operated kidney: a multi-  
10 institutional assessment using MAG3 renal scan. *World J Urol.* 2016 Jul;34(7):925-31.
- 11 25. Porpiglia F, Fiori C, Checcucci E, Amparore D, Bertolo R. Hyperaccuracy Three-  
12 dimensional Reconstruction Is Able to Maximize the Efficacy of Selective Clamping  
13 During Robot-assisted Partial Nephrectomy for Complex Renal Masses. *Eur Urol.* 2018  
14 Jan 6. pii: S0302-2838(17)31095-3. doi: 10.1016/j.eururo.2017.12.027. [Epub ahead of  
15 print]
- 16 26. Volpe A, Blute ML, Ficarra V, et al. Renal Ischemia and Function After Partial  
17 Nephrectomy: A Collaborative Review of the Literature. *Eur Urol.* 2015 Jul;68(1):61-74.  
18 doi: 10.1016/j.eururo.2015.01.025. Epub 2015 Feb 20. Review.
- 19 27. Winoker JS, Paulucci DJ, Anastos H, et al. Predicting Complications Following Robot-  
20 Assisted Partial Nephrectomy with the ACS NSQIP(®) Universal Surgical Risk  
21 Calculator. *J Urol.* 2017 Oct;198(4):803-809.

- 1 28. Zaid HB, Parker WP, Lohse CM, Cheville JC, Boorjian SA, Leibovich BC, Thompson  
2 RH. Patient factors associated with 30-day complications after partial nephrectomy: A  
3 contemporary update. *Urol Oncol*. 2017 Apr;35(4):153.
- 4 29. Abdel Raheem A, Alatawi A, Kim DK, et al. Outcomes of high-complexity renal  
5 tumours with a Preoperative Aspects and Dimensions Used for an Anatomical (PADUA)  
6 score of  $\geq 10$  after robot-assisted partial nephrectomy with a median 46.5-month follow-  
7 up: a tertiary centre experience. *BJU Int*. 2016 Nov;118(5):770-778.
- 8 30. Rajan S, Babazade R, Govindarajan SR et al. Perioperative factors associated with acute  
9 kidney injury after partial nephrectomy. *Br J Anaesth*. 2016 Jan;116(1):70-6.
- 10 31. Mamut AE, Violette PD, Rowe NE, Cui F, Luke PP. Measuring the impact of medical  
11 chronic kidney disease and diabetes mellitus on renal functional decline following  
12 surgical management of renal masses. *Urology*. 2016; 91:124-127
- 13 32. Zhang Z, Zhao J, Dong W, Remer E, Li J, Demirjian S, Zabell J, Campbell SC. Acute  
14 Kidney Injury after Partial Nephrectomy: Role of Parenchymal Mass Reduction and  
15 Ischemia and Impact on Subsequent Functional Recovery. *Eur Urol*. 2016; 69(4):745-52.
- 16 33. Porpiglia F, Fiori C, Bertolo R, et al. Long-term functional evaluation of the treated  
17 kidney in a prospective series of patients who underwent laparoscopic partial  
18 nephrectomy for small renal tumors. *Eur Urol*. 2012; 62(1):130-5.
- 19 34. Mouracade P, Kara O, Dagenais J, Maurice MJ, Nelson RJ, Malkoc E, Kaouk JH.  
20 Perioperative morbidity, oncological outcomes and predictors of pT3a upstaging for  
21 patients undergoing partial nephrectomy for cT1 tumors. *World J Urol*. 2017  
22 Sep;35(9):1425-1433. doi: 10.1007/s00345-017-2004-x. Epub 2017 Feb 14

- 1 35. Hansen J, Sun M, Bianchi M, Rink M, Tian Z, Hanna N, Meskawi M, Schmitges J,  
2 Shariat SF, Chun FK, Perrotte P, Graefen M, Karakiewicz PI. Assessment of cancer  
3 control outcomes in patients with high-risk renal cell carcinoma treated with partial  
4 nephrectomy. *Urology*. 2012; 80(2): 347-53.
- 5 36. Alanee S, Herberts M, Holland B, Dynda D. Contemporary Experience with Partial  
6 Nephrectomy for Stage T2 or Greater Renal Tumors. *Curr Urol Rep*. 2016 Jan;17(1):5.
- 7 37. Fero K, Hamilton ZA, Bindayi A, Murphy JD, Derweesh IH. Utilization and quality  
8 outcomes of cT1a, cT1b and cT2a partial nephrectomy: analysis of the national cancer  
9 database. *BJU Int*. 2017 Oct 15. doi: 10.1111/bju.14055. [Epub ahead of print]
- 10 38. Bensalah K, Pantuck AJ, Rioux-Leclercq N, et al. Positive surgical margin appears to  
11 have negligible impact on survival of renal cell carcinomas treated by nephron-sparing  
12 surgery. *Eur Urol*. 2010 Mar;57(3):466-71. doi: 10.1016/j.eururo.2009.03.048. Epub  
13 2009 Mar 31.
- 14 39. Khalifeh A, Kaouk JH, Bhayani S, et al. Positive surgical margins in robot-assisted  
15 partial nephrectomy: a multi-institutional analysis of oncologic outcomes (leave no tumor  
16 behind). *J Urol*. 2013 Nov;190(5):1674-9
- 17 40. Porpiglia F, Fiori C, Checcucci E, Amparore D, Bertolo R. Hyperaccuracy Three-  
18 dimensional Reconstruction Is Able to Maximize the Efficacy of Selective Clamping  
19 During Robot-assisted Partial Nephrectomy for Complex Renal Masses. *Eur Urol*. 2018  
20 Jan 6. pii: S0302-2838(17)31095-3. doi: 10.1016/j.eururo.2017.12.027.

21  
22  
23  
24

1 **Figures' Legend**

2 **Figure 1.** Chart showing the number of robot assisted partial nephrectomy (RAPN) during the  
3 study period.

4 **Figure 2.** Cumulative Proportion of Recurrence or metastasis (Kaplan-Meier curves) after  
5 stratification by A) pT stages according to TNM and B) presence of tumor thrombus (TT).

6 **Figure 3.** Cumulative Proportion of Recurrence or metastasis (Kaplan-Meier curves) after  
7 stratification by A) Fuhrman grade and B) presence of sarcomatoid pattern (sarc.).

8

9 **Supplementary Figure 1.** Study flow chart.

10 **Supplementary Figure 2.** Box and Whisker Plots showing Median, Inter-Quartile range (25-  
11 75%) and Minimum and Maximum values of the distribution (Min-Max) of A) Serum Creatinine  
12 (SCr) and B) estimated Glomerular Filtration Rate (eGFR). Overall ANOVA test showed a  
13 significant difference in SCr and eGFR (preoperative vs. postoperative,  $p < 0.001$ ). Conversely,  
14 no differences were found among the postoperative values of both SCr and eGFR ( $p = 0.798$  and  
15  $0.159$ , respectively).

16

17

18

19